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Case Report
A Case Report: Utilization of Topical Amphotericin in
Postoperative Mucormycosis
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Mucormycosis is a rare devastating fungal infection with a high mortality rate often associated with diabetic and immunosuppressed individuals. However, infections found in postoperative states and in immunocompetent patients are rare. Systemic liposomal amphotericin is
viewed as a first line treatment for mucormycosis in addition to aggressive debridement to
prevent the spread of infection. Literature describing the treatment of mucormycosis with
both systemic and topical amphotericin B is scarce. We present a case of an immunocompetent male admitted for perforated diverticulitis who received a left hemicolectomy with colostomy creation. During hospitalization, stool from the colostomy bag was reportedly leaking
into the wound. The patient was found to have extensive necrotic tissue with mold growing
in his postoperative incision site. The wound culture and pathology report confirmed mucormycosis. The patient was treated with intravenous (IV) liposomal amphotericin B, wound
dressings with an amphotericin/saline mixture twice daily and serial wound debridements. The
patient was discharged in stable condition with successful wound healing.
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Introduction

Mucormycosis is an infection typically caused
by fungi of the Mucorales order with species
such as Mucoraceae and Rhizopus being the
most common cause of infection. Mucormycosis is typically associated with immunocompromised individuals due to their inability to clear
the infection as a result of impaired phagocytosis. Impaired phagocytosis is also associated
with people with diabetes hence mucormycosis’ predilection for these patients. It has a high
mortality rate if not treated promptly with
antifungal and surgical debridement. This case
report highlights mucormycosis in an immunocompetent individual without diabetes and
the treatment with IV amphotericin B, surgical
debridement, and also a topical amphotericin
mixture applied in wound dressing changes,
which yielded a successful outcome.

Case Presentation

A 61-year-old Caucasian male with a history
of hypertension presented to the emergency
department with epigastric pain and shortness of breath. The patient was found to have
a perforated sigmoid diverticulitis with pneumoperitoneum on computerized tomography
imaging and admitted to the medical intensive
care unit. He received a left hemicolectomy
and colostomy creation. Postoperatively, the
patient’s condition was complicated by intubation and sepsis requiring vasopressors and
steroids. Peritoneal cultures from surgery grew
Bacterioides fragilis, Escherichia coli and group
C streptococci. The patient was medically
managed with cefepime, metronidazole and
fluconazole. However, he continued to have fevers despite negative blood and urine cultures.
Additionally, the patient’s colostomy bag was
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Figure 1. Post-op incision revealed extensive necrotic tissue with mold scattered throughout the
wound .
found to be leaking stool into the abdominal
incision. His post-op incision was reopened and
revealed extensive necrotic tissue with mold
scattered throughout the wound. (Figure 1) The
patient underwent serial surgical debridement
with deep wound cultures revealing mucormycosis, which was confirmed by pathology. He
was also started on intravenous (IV) liposomal
amphotericin B 5 mg/kg for a total dose of 450
mg daily and received topical wound treatment
with gauze saturated in 250 mg of amphotericin B mixed with 250 ml of normal saline. Twice
daily wound dressing changes with this mixture
were implemented. The patient was considered

for adjunct treatment with hyperbaric oxygen
with wound vac placement and amphotericin
irrigation. However, his postoperative wound
recovered remarkably well, (Figure 2), and he
was discharged to a long term acute care facility in stable condition with improved wound
healing 11 days after starting treatment with IV
amphotericin and topical amphotericin.

Discussion

Mucormycosis is a feared diagnosis for both clinicians and patients alike. With a mortality rate
of close to 80% associated with the infection,

Figure 2. Post operative wound healing upon patient discharge to a long term facility.
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immediate treatment with amphotericin is paramount upon the slightest clinical suspicion.1 As
in the case presented above, IV liposomal amphotericin B was immediately initiated alongside topical amphotericin B. To our knowledge,
there have been no reports in the use of topical
amphotericin B in postoperative mucormycosis
infections. Its use, however, has been reported
in two cases—one involving an infected abdominal mesh, in which 50 mg of amphotericin was
diluted in one liter of normal saline and applied
to wound packing,2 and another involving a
burn victim, in which 24 mg of amphotericin
was mixed in one liter of sterile water and
applied every eight hours as a wound dressing.3
Both cases resulted in successful wound healing after using topical amphotericin. Because
of mucormycosis’s propensity to cause rapid
necrosis,1 the decision to treat using adjunctive
topical amphotericin B was made in hopes of
limiting extensive, debilitating surgical debridement. Mucormycosis has been found to infect
the gastrointestinal tract.1 We suspected this
to be the source of our patient’s infection given
the rapid onset of tissue necrosis and visible
growth of mold in the wound after stool leaked
into the wound. Adjunct treatment with hyperbaric oxygen has been described in literature to
help promote angiogenesis and inhibit fungal
growth, thereby improving tissue growth and
recovery.4,5 Since our patient’s wound recovered remarkably well on systemic and topical
amphotericin, the decision was made not to
pursue hyperbaric oxygen therapy. Studies
from peer-reviewed literature have reported
that iron chelating agents such as deferasirox may also be considered to reduce fungal
burden and risk of fungal tissue invasion.1,4,6
IV amphotericin B and surgical debridement,
however, currently remain the gold standard
for the treatment of mucormycosis.1,5

should be conducted to further determine its
efficacy in the treatment of mucormycosis.
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For mucormycosis associated with large
wounds or postoperative wounds, treatment
should include IV liposomal amphotericin B,
wound dressing with an amphotericin B/saline mixture and serial surgical debridement.
Adjunct treatment with hyperbaric oxygen and
iron chelating agents may also be considered,
but more data is needed on its efficacy. However, with the lack of reports and research in
the use of topical amphotericin B, more studies

Author Affiliations

5.

6.

Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology,
presentation, and management. Clin Microbiol
Rev. 2005;18(3):556-569. https://doi.org/10.1128/
cmr.18.3.556-569.2005
Nadeem M, Zafar H, Effendi MS. Localised fungal infection in a prosthetic mesh
treated conservatively. BMJ Case Rep.
2011;2011:bcr0720103177. https://doi.org/10.1136/
bcr.07.2010.3177
Galvez AF, Lipka OL, Haith LR, et al. Treatment
of invasive mucormycosis with intravenous
isavuconazonium and topical amphotericin
B in a renal-impaired patient: case report
and review of the literature. Surg Infect Case
Rep. 2017;2(1):40-45. https://doi.org/10.1089/
crsi.2017.0007
Kruse M, Nielsen S, Berg A, Kaul S. Use of adjuvant hyperbaric oxygen therapy in a patient
with traumatic inoculation of mucormycosis
resulting in extremity amputation. Trauma Surg
Acute Care Open. 2020;5(1):e000434. Published 2020 Jan 26. https://doi.org/10.1136/tsaco-2019-000434
Sipsas NV, Gamaletsou MN, Anastasopoulou
A, Kontoyiannis DP. Therapy of mucormycosis. J Fungi (Basel). 2018;4(3):90. https://doi.
org/10.3390/jof4030090
Ibrahim AS, Spellberg B, Edwards J Jr. Iron acquisition: a novel perspective on mucormycosis
pathogenesis and treatment. Curr Opin Infect
Dis. 2008;21(6):620-625. https://doi.org/10.1097/
qco.0b013e3283165fd1

189

